Price T Rowe Associates Inc. MD Increases Stock Position in Glaukos Co. (NYSE:GKOS)

Price T Rowe Associates Inc. MD lifted its stake in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 13.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 35,182 shares of the medical instruments supplier's stock after buying an additional 4,227 shares during the quarter. Price T Rowe Associates Inc. MD owned approximately 0.06% of Glaukos worth $5,276,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Quadrant Capital Group LLC raised its position in shares of Glaukos by 3.3% during the 4th quarter. Quadrant Capital Group LLC now owns 2,300 shares of the medical instruments supplier's stock worth $345,000 after acquiring an additional 73 shares in the last quarter. Mutual of America Capital Management LLC raised its holdings in Glaukos by 1.1% during the fourth quarter. Mutual of America Capital Management LLC now owns 8,353 shares of the medical instruments supplier's stock worth $1,252,000 after purchasing an additional 89 shares in the last quarter. HighTower Advisors LLC lifted its position in shares of Glaukos by 2.8% during the 4th quarter. HighTower Advisors LLC now owns 3,298 shares of the medical instruments supplier's stock worth $495,000 after buying an additional 91 shares during the last quarter. Louisiana State Employees Retirement System boosted its holdings in shares of Glaukos by 0.4% in the 4th quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier's stock valued at $4,003,000 after buying an additional 100 shares in the last quarter. Finally, Handelsbanken Fonder AB raised its stake in Glaukos by 0.7% during the 4th quarter. Handelsbanken Fonder AB now owns 14,700 shares of the medical instruments supplier's stock worth $2,204,000 after acquiring an additional 100 shares in the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Glaukos Price Performance

NYSE:GKOS traded down $0.60 during mid-day trading on Friday, hitting $89.94. 511,969 shares of the company's stock traded hands, compared to its average volume of 682,126. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The company has a market cap of $5.14 billion, a PE ratio of -31.34 and a beta of 0.83. The firm's 50 day simple moving average is $94.87 and its 200 day simple moving average is $127.33. Glaukos Co. has a 1 year low of $77.10 and a 1 year high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.11. The firm had revenue of $106.66 million during the quarter, compared to the consensus estimate of $102.78 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The company's quarterly revenue was up 24.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.70) EPS. Sell-side analysts expect that Glaukos Co. will post -1.08 EPS for the current year.

Insider Activity at Glaukos

In other Glaukos news, insider Tomas Navratil sold 3,416 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the transaction, the insider now owns 72,437 shares of the company's stock, valued at $10,658,380.18. This represents a 4.50 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Alex R. Thurman sold 1,520 shares of Glaukos stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the sale, the chief financial officer now directly owns 53,431 shares of the company's stock, valued at approximately $5,708,568.04. This represents a 2.77 % decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Truist Financial reissued a "buy" rating and issued a $135.00 target price (down from $140.00) on shares of Glaukos in a research report on Thursday, May 1st. Stephens dropped their price objective on shares of Glaukos from $140.00 to $115.00 and set an "overweight" rating on the stock in a research note on Friday, May 2nd. Mizuho decreased their price objective on Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a research report on Wednesday, April 16th. Wells Fargo & Company downgraded Glaukos from an "overweight" rating to an "equal weight" rating and decreased their price target for the stock from $160.00 to $86.00 in a report on Thursday, May 1st. Finally, Needham & Company LLC cut their price objective on shares of Glaukos from $176.00 to $115.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $134.67.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.